Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics - NewsBreak

Vertex is spending $41 million upfront in a collaboration with Mammoth Biosciences. The two companies will develop gene-editing therapies targeting two genetic diseases. This deal shouldn't diminish Vertex's relationship with CRISPR Therapeutics. Vertex Pharmaceuticals (NASDAQ:VRTX) and its partner, CRISPR Therapeutics (NASDAQ:CRSP), have achieved significant progress with their drug targeting rare...